Live Analyst Rating Changes 8035 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Andy Hsieh
WB
Andy Hsieh
William Blair
Wall Street Analyst
★★☆☆☆
#2210
on 13Foresight · ranked by our own returns
44%
Success Rate
-5.4%
Average Return
12 of 27 calls profitable · -9.2% vs benchmark
📈 Across the calls we could measure, roughly 44% of Andy Hsieh's ratings turned a profit when each position was held for 1 year — averaging -5.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

104 Buy 46 Hold 0 Sell
Andy's Stock Coverage 22 ratings · 2026-07-14
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
KLRA
Kailera Therapeutics, Inc.
 Jul 07, 2026 BUY Strong Buy
+122.6% avg upside
5 analysts
 — ·
PYXS
Pyxis Oncology
 Jun 30, 2026 HOLD Strong Buy
+169.2% avg upside
13 analysts
 — -10.6%
LNTH
Lantheus
 Jun 27, 2026 BUY Strong Buy
-27.1% avg upside
20 analysts
 — -3.6%
EXEL
Exelixis
 Jun 22, 2026 BUY Buy
-24.1% avg upside
33 analysts
 — +9.1%
VKTX
Viking Therapeutics
 Jun 09, 2026 BUY Strong Buy
+87.3% avg upside
31 analysts
 — +33.0%
GPCR
Structure Therapeutics, Inc. Sponsored ADR
 Jun 08, 2026 BUY Strong Buy
+99.3% avg upside
17 analysts
 — +2.7%
TNYA
Tenaya Therapeutics
 Jun 03, 2026 BUY Strong Buy
+1087.9% avg upside
11 analysts
 — +10.7%
CRDF
Cardiff Oncology
 Jun 03, 2026 BUY Strong Buy
+651.7% avg upside
18 analysts
 — -13.6%
CRBP
Corbus Pharmaceuticals
 Jun 01, 2026 BUY Strong Buy
+282.1% avg upside
20 analysts
 — +18.4%
AARD
Aardvark Therapeutics, Inc.
 May 15, 2026 BUY Buy
+185.2% avg upside
12 analysts
 — +14.1%
AVIR
Atea Pharmaceuticals
 May 13, 2026 BUY Buy
+32.5% avg upside
6 analysts
 — +9.2%
ALT
Altimmune
 May 13, 2026 HOLD Strong Buy
+787.5% avg upside
20 analysts
 — -4.0%
KYNB
Kyntra Bio
 May 12, 2026 HOLD Strong Buy
+324.8% avg upside
15 analysts
 — ·
SKYE
Skye Bioscience
 May 12, 2026 BUY Strong Buy
+1433.5% avg upside
9 analysts
 — -15.2%
BIOA
BioAge Labs, Inc.
 May 11, 2026 HOLD Strong Buy
+120.9% avg upside
9 analysts
 — -2.8%
NKTR
Nektar Therapeutics
 May 07, 2026 BUY Strong Buy
+3.7% avg upside
25 analysts
 — -15.6%
AKTS
Aktis Oncology, Inc.
 Apr 29, 2026 BUY Strong Buy
+23.5% avg upside
8 analysts
$32.00
25.21% Upside
 ·
ZLDPF
Zealand Pharma
 Mar 06, 2026 HOLD Buy
+81.2% avg upside
11 analysts
 — ·
BRNS
Barinthus Biotherapeutics
 Aug 07, 2025 BUY Strong Buy
+601.1% avg upside
5 analysts
 — -56.0%
ATNM
Actinium Pharmaceuticals
 Dec 22, 2023 HOLD Strong Buy
+729.3% avg upside
11 analysts
 — -75.7%
BYSI
Beyondspring
 Dec 01, 2021 HOLD Hold
+444.0% avg upside
8 analysts
 — -88.4%
GILD
Gilead Sciences
 Feb 12, 2019 BUY Strong Buy
-8.9% avg upside
66 analysts
 — +6.3%
🔒 17 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Andy Hsieh — Frequently Asked Questions
How accurate are Andy Hsieh's stock ratings?
Based on the calls 13Foresight could measure, about 44% of Andy's ratings were profitable over a one-year hold, with an average return of -5.4% per rating, or -9.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Andy ranked on 13Foresight?
Andy Hsieh is currently ranked #2210 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Andy cover?
Andy most recently has ratings on KLRA, PYXS, LNTH, EXEL, VKTX, GPCR, TNYA, CRDF, CRBP, AARD, AVIR, ALT and 10 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.